Salesforce's $8 billion buyout of Informatica boosts its AI and data integration business, influencing ETFs with stakes in ...

Rocket Pharmaceuticals faces trial delays, multiple downgrades, and reduced success expectations following RP-A501 safety ...

Cryptocurrency markets were down on Wednesday despite Vice President JD Vance’s vow of support for the digital asset industry ...

Analyst initiates Primo Brands with $42 target, citing $300M synergy-driven EBITDA gains and strong bottled water category ...

Ultragenyx sees rising revenue and analyst support as key drug launch approaches, with potential profitability projected for ...